Hepatitis C Virus Linked to Oncogenesis: Studies Highlight Recent Research

Strategic Insights -

Recent studies from the United States and Japan shed light on the complex relationship between hepatitis C virus (HCV) infection and oncogenesis. Research suggests that HCV can stimulate liver cell growth and tumorigenesis, lead to the activation of nitric oxide synthase-mediated mutagenesis, and potentially cause intrahepatic cholangiocarcinoma.

Key Takeaways:

  • Study 1, published in the Journal of Cellular Physiology, found that HepG2 cells stably transfected with a full-length, infectious HCV cDNA demonstrated consistent replication of HCV for more than 3 years, leading to liver cell growth and tumorigenesis.
  • Researchers, led by B.S. Sun, determined that the HCV core protein and NS5B were detectable in the cells, and HCV stimulated HepG2 cell growth and survival in culture and accelerated tumor growth in SCID mice.
  • Study 2, published in the Journal of Virology, found that HCV infection activates the immunologic (type II) isoform of nitric oxide synthase and enhances DNA damage and mutations of cellular genes. The HCV core and NS3 proteins induced the production of NO and DNA breaks.
  • Study 3, published in Cancer Science, found that HCV infection may be a likely etiology of intrahepatic cholangiocarcinoma (ICC). Researchers, led by S. Yamamoto, detected HCV seropositivity in 36% of ICC patients and 3% of controls.
  • According to the studies, HCV infection can stimulate the production of NO, leading to DNA breaks and enhanced DNA mutation. This sequence of events provides a mechanism for HCV pathogenesis and oncogenesis.
  • The studies highlight the potential link between HCV infection and the development of various types of cancer, including liver carcinoma and intrahepatic cholangiocarcinoma.
  • Study 1 was conducted by B.S. Sun and colleagues at Thomas Jefferson University, Department of Pathology, Anatomy and Cell Biology.
  • Study 2 was conducted by K. Machida and colleagues at the University of Southern California, Keck School of Medicine, Department of Molecular Microbiology & Immunology.
  • Study 3 was conducted by S. Yamamoto and colleagues at Osaka City University, Graduate School of Medicine, Department of Gastroenterology & Hepatobiliary Pancreat Surgery.

Statistics:

  • HCV cDNA was detectable in HepG2 cells for more than 3 years (Sun et al., 2004).
  • 36% of ICC patients tested positive for HCV antibodies, while 3% of controls did (Yamamoto et al., 2004).
  • The odds ratio (OR) for association of anti-HCV antibodies with development of ICC was 16.87 (95% CI, 5.69 to 50.00) (Yamamoto et al., 2004).
  • By multivariate analysis, anti-HCV antibodies, elevated alanine aminotransferase, decreased serum albumin, and decreased platelet count were found to be independent risk factors for ICC development (Yamamoto et al., 2004).
  • The iNOS promoter was activated more than five-fold in HCV-infected cells, as revealed by a luciferase reporter assay driven by the iNOS promoter (Machida et al., 2004).
  • The core protein also enhanced the mutation frequency of cellular genes in hepatocytes derived from HCV core transgenic mice compared with control mice (Machida et al., 2004).

Sources:

  • Sun, B.S., et al. "Hepatitis C virus replication in stably transfected HepG2 cells promotes hepatocellular growth and tumorigenesis." Journal of Cellular Physiology, vol. 201, no. 3, 2004, pp. 447-458.
  • Machida, K., et al. "Hepatitis C virus infection activates the immunologic (type II) isoform of nitric oxide synthase and thereby enhances DNA damage and mutations of cellular genes." Journal of Virology, vol. 78, no. 16, 2004, pp. 8835-8843.
  • Yamamoto, S., et al. "Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma." Cancer Science, vol. 95, no. 7, 2004, pp. 592-595.